ENA Respiratory Pty Ltd is a clinical-stage biotechnology company headquartered in Melbourne, Australia, with operations in the USA. Founded in 2020 as a spin-out from ENA Therapeutics, it focuses on developing intranasal antiviral host defense enhancers to prevent symptomatic respiratory viral infections and severe complications in at-risk populations.
The company's lead candidate, INNA-051, is a first-in-class small molecule TLR2/6 agonist formulated as a once-weekly dry powder nasal spray. It primes the nasal epithelium's innate immune response, upregulating antiviral Type III interferons to combat a broad range of viruses, including SARS-CoV-2, influenza, rhinovirus, and RSV, at the initial site of infection.
INNA-051 has demonstrated safety and efficacy in Phase I studies, including faster recovery from H3N2 influenza challenge. It is currently in a Phase II community-based trial (POSITS) evaluating its ability to reduce symptomatic illness in adults at high exposure risk. The therapy features a shelf-stable powder delivery system via Aptar Pharma's Unidose device with moisture protection.
Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.
